Join us in our fight to help prevent dementia due to Alzheimer's disease
MAP is a research study looking at whether Metformin can help prevent memory decline for people with mild memory concerns.
How to participate
Requirements
- Must be 55-90 years old
- Notice changes in memory
- Are not currently taking Metformin
- Are not diagnosed with diabetes
Enrollment for this study is now closed.
About the study
MAP is a research study looking at an existing drug used for diabetes prevention. The study tests if this drug can help prevent a decline in memory and thinking abilities for people with mild memory problems. It is a randomized study in which you will take either Metformin (Glucophage® XR) or a placebo.
Randomized means the trial participants will have an equal opportunity of getting the study drug or placebo. A placebo is a pill that looks the same as the study drug, but has no medicine.
There will be no charge for the study drug or study visits.
This study is completely voluntary.
MAP is a multi-center study, where people can take part in the study throughout the United States. It is funded by the National Institutes of Health (NIH) through the National Institute on Aging (NIA). Our researchers are experienced in running research studies. They are also experts in the field of memory loss, dementia, and Alzheimer’s disease. Join us in our search for treatments to improve the lives of those with memory problems due to Alzheimer’s disease.
Frequently Asked Questions
What is involved?
Who can join?
Will participants be compensated?
How to participate?